Johnson Controls (JCI) Form 4: Executive sale under 10b5-1 plan
Rhea-AI Filing Summary
Johnson Controls International (JCI) insider sale reported. Nathan D. Manning, VP and President, Americas, reported a sale of 1,422 ordinary shares on 09/02/2025 at a price of $105.06 per share, leaving him with 139,458.9 shares beneficially owned. The filing states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2024, and the Form 4 was signed by an attorney-in-fact on 09/04/2025. The filing identifies the reporter's Milwaukee, WI address and confirms this is an individual Form 4 filing. No derivative transactions or other securities classes are disclosed in this Form 4.
Positive
- Transaction executed under a Rule 10b5-1 trading plan, indicating pre-established, documented trading procedures
- Form 4 timely discloses key details: shares sold (1,422), price ($105.06), transaction date (09/02/2025), and remaining beneficial ownership (139,458.9)
Negative
- Insider disposition of shares (1,422 sold) reduces the reporting person's stake
- No additional context provided about the purpose of the sale beyond the 10b5-1 plan (e.g., tax or personal liquidity)
Insights
TL;DR: Routine insider sale executed under a 10b5-1 plan, reducing holdings modestly to ~139.5k shares.
The report documents a non-derivative sale of 1,422 ordinary shares at $105.06 each on 09/02/2025 by an executive officer. The transaction is explicitly tied to a Rule 10b5-1 trading plan adopted 09/12/2024, which typically provides preclearance and affirmative defense to claims of trading on material nonpublic information. The Form shows no additional derivative activity and indicates an individual filing. For investors, this is a transparent disclosure of insider liquidity but, standing alone, does not indicate material change to insider ownership or control.
TL;DR: Disclosure aligns with good governance practices: sale under a documented 10b5-1 plan and timely Form 4 filing.
The filing identifies the reporting person, relationship to the issuer, transaction date, price, and remaining beneficial ownership, and includes an explanation that the sale was pursuant to a 10b5-1 plan. The Form appears complete for this single transaction and is signed by an attorney-in-fact. From a governance perspective, use of a 10b5-1 plan and prompt reporting support procedural compliance; the filing contains no indications of exception or unusual accommodation.